McDermott Will & Schulte advised LATTICE MEDICAL, a French medtech company specializing in tissue engineering, on its €43 million Series B financing round, one of the largest of the year in the French medtech sector.

This major milestone will enable the company to accelerate the clinical development of MATTISSE, its breakthrough medical device designed for post-cancer breast reconstruction.

The financing round was led by the SPI Fund, managed by Bpifrance on behalf of the French State under the France 2030 initiative, and supported by Blast.Club, Sprim, qualified investors gathered under TIDJEE, as well as historical shareholders EIC Fund, Captech Santé, Nord France Amorçage, and FIRA Nord Est. The round also includes non-dilutive financing from banking partners and two France 2030 programs – M3DINPRINT and LIPOTEC.

The McDermott team that advised LATTICE MEDICAL comprised Emmanuelle Trombe, Lucie Martin, Natacha Vasak and Pauline Orliange (Corporate), Charles de Raignac (Intellectual Property), Côme de Saint Vincent and Paul-Henry de Laguiche (Tax) and Caroline Noyrez (regulatory).

Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,750+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.